Content
Recession Watch: Spiking Layoffs
Article By:
John Rubino
Read
Sunday, January 14, 2024 4:36 AM EDT
Healthy economies have a natural background rate of hiring and firing, as employers adjust to changes in their environment. But when the firing part of the process starts to dominate, trouble frequently follows.
Gold Biding Time, Bitcoin Prime Time
Article By:
Mark Mead Baillie
Read
Sunday, January 14, 2024 4:16 AM EDT
Since the SEC’s cautionary "Gensler Granting” of the ETFs this past Thursday, Wall Street treated Bitcoin as essentially it does “all things” anticipated: the rumor having been bought, the news then was sold.
Huawei Will Be The Next To Challenge Tesla In Autonomous Driving
Article By:
Tyler Durden
Read
Saturday, January 13, 2024 1:40 PM EDT
The bad news just keeps stacking up for Tesla. This week it was announced the company was shuttering production at its Berlin plant. To cap off the week, Huawei is now aiming to pull ahead of Tesla in the race for autonomous vehicles.
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By:
ChinaBio® Today
Read
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
German Trade Rebounds In November
Article By:
Carsten Brzeski
Read
Monday, January 8, 2024 6:47 AM EDT
German trade finally rebounds, but a very weak increase in industrial orders shows that the economy is still far from a substantial recovery.
In this article: EWG
What’s The Actual Strength Of The Labor Market? CPS Vs CES Vs ADP Vs ISM
Article By:
Menzie Chinn
Read
Sunday, January 7, 2024 4:10 PM EDT
Some commentators have focused on the sharp declines in civilian employment as well as the ISM services employment diffusion index as signaling greater weakness than suggested by the establishment survey.
How To Use Social Media To Make More Money In Your Business
Video By:
Camari Ellis
Watch
Sunday, January 7, 2024 10:40 AM EDT
In this video, we delve into strategies to leverage platforms like Facebook, Twitter, and LinkedIn to enhance your brand's visibility and engagement.
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Article By:
ChinaBio® Today
Read
Sunday, January 7, 2024 7:20 AM EDT
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China) for AVZO-021 to Avenzo Therapeutics.
Mapped: Which Is The Best U.S. City For Entry-Level Jobs By Pay?
Article By:
Jeff Desjardins
Read
Sunday, January 7, 2024 5:36 AM EDT
To find the best U.S. city and state for well-paid entry-level jobs, NeoMam Studios visualizes data from Resume.io showing the percentage of local entry-level job listings that offer a salary above (and below) a city or state’s median hourly wages.
America’s Boring Superweapon
Podcast By:
Felix Salmon
Listen
Monday, January 1, 2024 8:14 AM EDT
This week, Felix Salmon, Emily Peck, and Elizabeth Spiers chat with Henry Farrell, author of Underground Empire: How America Weaponized the World Economy. American hegemony has shifted from guns and tanks to SWIFT codes and internet policies.
Your Paycheck In 2024
Article By:
Ironman
Read
Monday, January 1, 2024 6:52 AM EDT
Welcome to 2024! We know you're here to estimate what your take home pay will look like after all those federal income and payroll taxes have been taken out of your paycheck. But do you know when federal income tax withholding became a thing?
The Financial Distress Puzzle
Article By:
Alpha Architect
Read
Monday, January 1, 2024 4:56 AM EDT
That riskier assets should command higher expected returns is a basic of asset pricing theories. Clearly, financial distress is a risk characteristic, but it presents a puzzle, as there has not been a linear relationship between it and stock returns.
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Article By:
ChinaBio® Today
Read
Sunday, December 31, 2023 11:00 AM EDT
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program. Initially, Elpiscience will receive up to $37 million.
Learn To Love Company Debt
Article By:
The Dividend Guy
Read
Thursday, December 28, 2023 8:00 AM EDT
I see leverage through debt as a brilliant way for companies to create wealth. Most successful businesses use leverage to their advantage.